18 research outputs found
Assessment of size of TST in relation to T-SPOT.TB and TST results.
<p>IQR: interquartile range; + indicates positive result; – indicates negative result.</p
Association between RD1 antigens at five years and at follow-up.
<p>Results are presented as logs (to base 10) of spot forming units for the two RD1 antigens. (a) ESAT-6 at five years vs.CFP-10 at five years (n = 179); r<sub>s</sub> = 0.7548 (b) ESAT-6 follow-up vs. CFP-10 follow-up (n = 158); r<sub>s</sub> = 0.7838 (c) CFP-10 at five years vs. CFP-10 at follow-up (n = 127); r<sub>s</sub> = 0.3125 (d) ESAT -6 at five years vs. ESAT-6 at follow-up (n = 163); r<sub>s</sub> = 0.3576.</p
T-SPOT.TB assay results at five years and at follow-up: Protocol 2.
<p>T-SPOT.TB assay results at five years and at follow-up: Protocol 2.</p
T-SPOT.TB assay results at five years and at follow-up: Protocol 1.
<p>T-SPOT.TB assay results at five years and at follow-up: Protocol 1.</p
Agreement between T-SPOT.TB and TST results.
<p>+ indicates positive result; – indicates negative result.</p
<i>Mycobacterium tuberculosis</i> infection prevalence estimates by different measures.
<p>The denominator is 907 for all the estimates.</p>*<p>All but 9 of the baseline T-SPOT.TB positives were followed up. Prevalence doesn’t change when the 9 are subtracted from the denominator.</p>**<p>Does not take into account the baseline T-SPOT.TB negatives that were not followed up, yet might have turned positive on follow-up. This is not likely to change the prevalence estimates, since most (96%) of the baseline negatives that were followed up remained negative.</p
Median difference in spot counts to ESAT-6 and CFP-10 for participants whose T-SPOT.TB result varied between age five and follow-up.
<p>SFUs: spot forming units; IQR: interquartile range; + indicates positive result; – indicates negative result.</p
The effect of maternal anthelminthic treatment on childhood disease incidence by maternal helminth status (from birth to 5 years).
<p>The effect of maternal anthelminthic treatment on childhood disease incidence by maternal helminth status (from birth to 5 years).</p
Effect of quarterly albendazole from age 15 months to 5 years on infectious disease incidence in children.
<p>Kaplan-Meier survival estimates for time to first (or only episode) of (a) malaria, (b) diarrhoea and (c) pneumonia during the intervention period, comparing children who received quarterly albendazole with those who received placebo. Numbers shown in the tables are number of events (in brackets) and number of children at risk.</p
The effect of anthelminthic treatment during pregnancy on incidence of malaria, diarrhoea, pneumonia and eczema during early childhood (from birth to 5 years).
<p>There was no evidence of interaction between maternal albendazole and praziquantel treatments, therefore the effects of each treatment were examined independently.</p